Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2414-2416

  Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; AZACITIDINE; CYTARABINE; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; BLAST CELL; CANCER REGRESSION; CHROMOSOME 5; CLINICAL FEATURE; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG MECHANISM; EDEMA; EDITORIAL; EPIGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PAIN; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RASH; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NOTE;

ANTINEOPLASTIC AGENTS; ARSENICALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MYELODYSPLASTIC SYNDROMES; OXIDES; TREATMENT OUTCOME;

EID: 33745009313     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4759     Document Type: Editorial

References (14)

1. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997; erratum appears in Blood 91:1100,1998
2. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002
3. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005
4. Cheson BD, Jasperse DM, Simon R, et al: A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857-1864, 1986
5. Abrahm J, Besa EC, Hyzinski M, et al: Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: Inhibition of growth of the patient's malignant monocytoid clone. Blood 67:1323-1327, 1986
6. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463, 2004
7. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
8. Raza A, Qawi H, Lisak L, et al: Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95:1580-1587, 2000
9. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004
10. Soignet SL, Maslak P, Wang ZG, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
11. Schiller GJ, Slack J, Hainsworth JD, et al: A phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24:2456-2464, 2006
12. Vey N, Bosly A, Guerci A, et al: Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study. J Clin Oncol 24:2465-2471, 2006
13. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
14. Silverman R, McKenzie DR, Peterson B, et al: Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and International Working Group (IWG) critieria for myelodysplastic syndrome (MDS). Blood 106:525a, 2005 (abstr 1848)